Stocks
Eledon Pharmaceuticals, Inc.ELDN
NASDAQHealthcareBiotechnology$2.30
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for solid organ transplantation and autoimmune diseases. Its lead candidate, tegoprubart, is an anti-CD40 ligand antibody in Phase 2 trials for kidney transplantation. Investors track the stock for its potential to address high unmet need in transplant rejection and its progress in a competitive immunotherapy landscape.
52W Range: $1.35-$4.60
Congressional Interest in Eledon Pharmaceuticals, Inc. (ELDN)
No congressional trades have been disclosed for Eledon Pharmaceuticals, Inc. (ELDN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ELDN?
No congressional trades found for this stock.